Denali Therapeutics Inc., also recognized by its ticker DNLI, is a publicly traded biopharmaceutical company that specializes in developing treatments for neurodegenerative diseases. The company was founded in 2013 by former Genentech executives Ryan Watts, Alex Schuth, and Marc Tessier-Lavigne. It is currently headquartered in South San Francisco, California.
The mission of Denali Therapeutics is to conquer degeneration, aiming to deliver effective treatments for neurodegenerative diseases that are known to cause significant suffering for patients and their families. These diseases range from Alzheimer's and Parkinson's to ALS (Amyotrophic Lateral Sclerosis) and other rare genetic disorders of the nervous system.
Denali's approach to tackling these diseases is cutting-edge and multi-faceted. Focused on overcoming the blood-brain barrier, which has been a longstanding obstacle in treating neurological diseases, Denali uses its proprietary technology called the Transport Vehicle (TV) platform. This technology allows therapeutic proteins and other drugs to cross the blood-brain barrier and directly target the disease-causing activities in the brain.
Denali Therapeutics’ portfolio includes multiple ongoing clinical trials in varied stages, with several drugs for Parkinson's Disease, Alzheimer's Disease, ALS, and other neurodegenerative disorders. Denali has also built partnerships with household names in pharmaceuticals such as Biogen and Takeda, working collaboratively to develop therapeutic treatments using its signature technology.
As a publicly-traded company on NASDAQ since 2017, Denali has shown commitment and potential in its pursuit. It continues to be a promising enterprise in biopharma, attracting investor attention with its progress and innovative approach to neurological degenerative disease treatment. Denali's transparent commitment to therapeutic research and development, along with its effort to decode and defuse some of the most challenging neurologic disorders, places it at the forefront of biopharmaceutical innovation.
However, biopharmaceutical research and development is inherently risky, with high costs and no guarantee of success. Therefore, while the goals of Denali Therapeutics are laudable and its work's potential immense, financial success is far from assured. Nevertheless, Denali's dedication to overcoming some of the most significant challenges in neurodegenerative disease treatment makes it a noteworthy player in the wider biopharmaceutical sector.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Denali Therapeutics Director Nancy Thornberry sold 11,439 shares of the company's stock on September 2, 2026, totaling $261,929. This transaction was disclosed in a recent SEC filing. The article notes that a premium subscription is required to view the full MT Newswires report.
This article provides an analysis of Denali Therapeutics Inc. (NASDAQ: DNLI) based on AI-generated signals and institutional trading strategies. It highlights a weak near-term sentiment but strong long-term outlook, with specific entry and exit points, targets, and stop losses for various risk profiles. The analysis also details support and resistance levels across different time horizons.
Great Lakes Advisors LLC has purchased a new stake of 145,045 shares in Denali Therapeutics Inc. (NASDAQ:DNLI) valued at approximately $3,731,000 during the second quarter. Other institutional investors have also adjusted their holdings in Denali Therapeutics, and the company's stock has a "Moderate Buy" consensus rating from analysts with a target price of $35.92. Denali Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases.
Bank of America Corp DE increased its stake in Denali Therapeutics Inc. (NASDAQ:DNLI) by 21.7% in the first quarter, now holding 1.13 million shares valued at approximately $21.8 million. Institutional investors collectively own 92.92% of DNLI, and analysts maintain a "Moderate Buy" rating with an average target price of $35.92. Despite missing EPS estimates, Denali exceeded revenue expectations and continues to develop therapies for neurodegenerative diseases.
Denali Therapeutics (DNLI) reported Q2 2026 revenue of US$3.6 million and a net loss of US$127.55 million. While the company's shares have shown strong recent momentum, trading at US$24.40, there are conflicting views on its valuation, with one narrative suggesting it's 41.9% undervalued at $42.00, while a DCF model indicates it's expensive at its current price. The company's valuation is heavily influenced by the performance of its AVLAYAH product and the pipeline risks.
SCS Capital Management LLC has acquired a new position in Denali Therapeutics Inc. (NASDAQ:DNLI), purchasing 197,998 shares valued at approximately $5.1 million. This makes them a new institutional investor in the biopharmaceutical company, which has seen significant interest from other large institutional investors as well. Denali Therapeutics maintains a "Moderate Buy" consensus rating from analysts, with a target price of $35.92, despite a recent earnings per share miss.
Denali Therapeutics Inc. CEO, Ryan J. Watts, donated 32,220 shares of common stock to a donor-advised fund on August 12, 2026, as disclosed in an SEC Form 4 filing. This charitable gift, valued at $0, was reported on August 14, 2026. Following the donation, Watts maintains significant direct and indirect ownership in the company through a family trust and directly held shares, including unvested RSUs.